Cyclization of the urokinase receptor-derived Ser-Arg-Ser-Arg-Tyr peptide generates a potent inhibitor of trans-endothelial migration of monocytes

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Yousif, Ali Munaim ^a   Minopoli, Michele ^b   Bifulco, Katia ^b   Ingangi, Vincenzo ^b,c   Di Carluccio, Gioconda ^b   Merlino, Francesco ^a   Motti, Maria Letizia ^d   Grieco, Paolo ^a   Carriero, Maria Vincenza ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FORMYLPEPTIDE RECEPTOR LIKE 1; SERYLARGINYLSERYLARGINYLTYROSINE; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; PEPTIDE; PROTEIN BINDING;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL FUNCTION; CELL MOTILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYCLIZATION; DRUG DETERMINATION; DRUG EFFECT; DRUG MECHANISM; DRUG PROTEIN BINDING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC50; MIGRATION INHIBITION; MOLECULAR DYNAMICS; MONOCYTE; NONHUMAN; PROTEIN DETERMINATION; PROTEIN FUNCTION; RAT; SEQUENCE ANALYSIS; AMINO ACID SEQUENCE; ANIMAL; CELL LINE; CHEMISTRY; DRUG EFFECTS; MACROPHAGE; METABOLISM; PHYSIOLOGY; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; TUMOR CELL LINE;

MAMMALIA; RATTUS;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLIZATION; MACROPHAGES; MONOCYTES; PEPTIDES; PROTEIN BINDING; RATS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION;

EID: 84929094259     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0126172     Document Type: Article

References (41)

1. Plesner T, Behrendt N, Ploug M. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR. Stem Cells. 1997; 15:398-408. PMID: 9402652
2. Mondino A, Blasi F. uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol. 2004; 25:450-455. PMID: 15275645
3. Gyetko MR, Sud S, Kendall T, Fuller JA, Newstead MW, Standiford TJ. Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection. J Immunol. 2000; 165:1513-1519. PMID: 10903758
4. Gyetko MR, Sud S, Sonstein J, Polak T, Sud A, Curtis JL. Antigen-driven lymphocyte recruitment to the lung is diminished in the absence of urokinase-type plasminogen activator (uPA) receptor, but is independent of uPA. J Immunol. 2001; 167:5539-5542. PMID: 11698423
5. Rijneveld AW, Levi M, Florquin S, Speelman P, Carmeliet P, van Der Poll T. Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia. J Immunol. 2002; 168:3507-3511. PMID: 11907112
6. Gyetko MR, Aizenberg D, Mayo-Bond L. Urokinase deficient and urokinase receptor-deficient mice have impaired neutrophil antimicrobial activation in vitro. Leukoc Biol. 2004; 76: 648-656. PMID: 15240745
7. Montuori N, Selleri C, Ragno P. The urokinase-receptor in infectious diseases Infez Med. 2012; 20 Suppl 2:8-12. PMID: 23042000
8. Thunø M, Macho B, Eugen-Olsen J. SuPAR the molecular crystal ball. Dis Markers. 2009; 27:157-172. doi: 10.3233/DMA-2009-0657 PMID: 19893210
9. Huttunen R, Syrjänen J, Vuento R, Hurme M, Huhtala H, Laine J, et al. Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study. J Intern Med. 2011; 270:32-40. doi: 10.1111/j.1365-2796.2011.02363.x PMID: 21332843
10. Ploug M, Rønne E, Behrendt N, Jensen AL, Blasi F, Danø K. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem. 1991; 266:1926-1933. PMID: 1846368
11. Ploug M, Ellis V. Structure-function relationships in the receptor for urokinase-type plasminogen activator-comparison to other members of the Ly-6 family and snake venom alpha- neurotoxins. FEBS Lett. 1994; 349:163-168. PMID: 8050560
12. Bifulco K, Votta G, Ingangi V, Di Carluccio G, Rea D, Losito S, et al. Urokinase receptor promotes ovarian cancer cell dissemination through its 84-95 sequence. Oncotarget. 2014; 5:4154-4169. PMID: 24980826
13. Carriero MV, Stoppelli MP. The urokinase-type plasminogen activator and the generation of inhibitors of urokinase activity and signaling. Curr Pharm Des. 2011; 17:1944-1961. PMID: 21711235
14. Resnati M, Pallavicini I, Wang JM, Oppenheim J, Serhan CN, Romano M, et al. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci USA. 2002; 99:1359-1364. PMID: 11818541
15. Gargiulo L, Longanesi-Cattani I, Bifulco K, Franco P, Raiola R, Campiglia P, et al. Cross-talk between fMLP and vitronectin receptors triggered by urokinase receptor-derived SRSRY peptide. J Biol Chem. 2005; 280: 25225-25232. PMID: 15866865
16. Bifulco K, Longanesi-Cattani I, Gala M, Di Carluccio G, Masucci MT, Pavone V, et al. The soluble form of urokinase receptor promotes angiogenesis through its Ser88-Arg-Ser-Arg-Tyr92 chemotactic sequence. J Thromb Haemost. 2010; 8:2789-2799. doi: 10.1111/j.1538-7836.2010.04075.x PMID: 20880257
17. Furlan F, Orlando S, Laudanna C, Resnati M, Basso V, Blasi F, et al. The soluble D2D3(88-274) fragment of the urokinase receptor inhibits monocyte chemotaxis and integrin-dependent cell adhesion. J Cell Sci. 2004; 117:2909-2916. PMID: 15173320
18. Montuori N, Carriero MV, Salzano S, Rossi G, Ragno P. The cleavage of the urokinase receptor regulates its multiple functions. J Biol Chem. 2002; 277:46932-46939. PMID: 12297505
19. Yuan C, Huang M. Does the urokinase receptor exist in a latent form? Cell Mol Life Sci. 2007; 64:1033-1037. PMID: 17372678
20. Gardsvoll H, Jacobsen B, Kriegbaum MC, Behrendt N, Engelholm L, Østergaard S, et al. Conformational regulation of urokinase receptor function: impact of receptor occupancy and epitope-mapped monoclonal antibodies on lamellipodia induction. J Biol Chem. 2011; 286:33544-33556. doi: 10.1074/jbc.M111.220087 PMID: 21799009
21. Barinka C, Parry G, Callahan J, Shaw DE, Kuo A, Bdeir K, et al. Structural basis of interaction between urokinase-type plasminogen activator and its receptor. J Mol Biol. 2006; 363: 482-495. PMID: 16979660
22. Xu X, Gårdsvoll H, Yuan C, Lin L, Ploug M, Huang M. Crystal structure of the urokinase receptor in a ligand-free form. J Mol Biol. 2012; 416: 629-641. doi: 10.1016/j.jmb.2011.12.058 PMID: 22285761
23. Bifulco K, Longanesi-Cattani I, Franco P, Pavone V, Mugione P, Di Carluccio G, et al. Single amino acid substitutions in the chemotactic sequence of urokinase receptor modulate cell migration and invasion. PLoS One. 2012; 7:e44806. doi: 10.1371/journal.pone.0044806 PMID: 23049759
24. Carriero MV, Longanesi-Cattani I, Bifulco K, Maglio O, Lista L, Barbieri A, et al. Structure-based design of an urokinase-type plasminogen activator receptor-derived peptide inhibiting cell migration and lung metastasis. Mol Cancer Ther. 2009; 8:2708-2717. doi: 10.1158/1535-7163.MCT-09-0174 PMID: 19706734
25. Bifulco K, Longanesi-Cattani I, Gargiulo L, Maglio O, Cataldi M, De Rosa M, et al. An urokinase receptor antagonist that inhibits cell migration by blocking the formyl peptide receptor. FEBS Lett. 2008; 582:1141-1146. doi: 10.1016/j.febslet.2008.03.001 PMID: 18339322
26. Bifulco K, Longanesi-Cattani I, Liguori E, Arra C, Rea D, Masucci MT, et al. A Urokinase Receptor-Derived Peptide Inhibiting VEGF-Dependent Directional Migration and Vascular Sprouting. Mol Cancer Ther. 2013; 10:1981-1993.
27. Carriero MV, Bifulco K, Minopoli M, Lista L, Maglio O, Mele L, et al. UPARANT: a urokinase receptorderived peptide inhibitor of VEGF-driven angiogenesis with enhanced stability and in vitro and in vivo potency. Mol Cancer Ther. 2014; 13:1092-1104. doi: 10.1158/1535-7163.MCT-13-0949 PMID: 24705350
28. Gao JL, Murphy PM. Species and subtype variants of the N-formyl peptide chemotactic receptor reveal multiple important functional domains. J Biol Chem. 1993; 268:25395-25401. PMID: 8244972
29. Tsubota Y, Frey JM, Tai PW, Welikson RE, Raines EW. Monocyte ADAM17 promotes diapedesis during transendothelial migration: identification of steps and substrates targeted by metalloproteinases. J Immunol. 2013; 190:4236-4244. doi: 10.4049/jimmunol.1300046 PMID: 23479224
30. Ronald JA, Ionescu CV, Rogers KA, Sandig M. Differential regulation of transendothelial migration of THP-1 cells by ICAM-1/LFA-1 and VCAM-1/VLA-4. J Leukoc Biol. 2001; 70:601-609. PMID: 11590197
31. Mackay CR. Moving targets: cell migration inhibitors as new anti-inflammatory therapies. Nat Immunol. 2008; 9:988-998. doi: 10.1038/ni.f.210 PMID: 18711436
32. Salmi M, Jalkanen S. Ectoenzymes controlling leukocyte traffic. Eur J Immunol. 2012; 42:284-292. doi: 10.1002/eji.201142223 PMID: 22359101
33. Griffith JW, Luster AD. Targeting cells in motion: Migrating toward improved therapies. Eur J Immunol. 2013; 43:1430-1435. doi: 10.1002/eji.201243183 PMID: 23580465
34. Blasi F. uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways? Immunol Today. 1997; 18:415-417. PMID: 9293155
35. Miettinen HM, Mills JS, Gripentrog JM, Dratz EA, Granger BL, Jesaitis AJ. The ligand binding site of the formyl peptide receptor maps in the transmembrane region. J Immunol. 1997; 159:4045-4054. PMID: 9378994
36. Le Y, Murphy PM, Wang JM. Formyl-peptide receptors revisited. Trends Immunol. 2002; 23:541-548. PMID: 12401407
37. Bae YS, Song JY, Kim Y, He R, Ye RD, Kwak JY, et al. Differential activation of formyl peptide receptor signaling by peptide ligands. Mol Pharmacol. 2003; 64:841-847. PMID: 14500740
38. Lee HY, Kim SD, Baek SH, Choi JH, Bae YS. Role of formyl peptide receptor 2 on the serum amyloid A-induced macrophage foam cell formation. Biochem Biophys Res Commun. 2013; 433:255-259. doi: 10.1016/j.bbrc.2013.03.002 PMID: 23500463
39. Liu M, Zhao J, Chen K, Bian X, Wang C, Shi Y, Wang JM. G protein-coupled receptor FPR1 as a pharmacologic target in inflammation and human glioblastoma. Int Immunopharmacol. 2012; 14:283-288. doi: 10.1016/j.intimp.2012.07.015 PMID: 22863814
40. Montuori N, Bifulco K, Carriero MV, La Penna C, Visconte V, Alfano D, et al. The cross-talk between the urokinase receptor and fMLP receptors regulates the activity of the CXCR4 chemokine receptor. Cell Mol Life Sci. 2011; 68:2453-2467. doi: 10.1007/s00018-010-0564-7 PMID: 20972812
41. Rao T, Ruiz-Gómez G, Hill TA, Hoang HN, Fairlie DP, Mason JM. Truncated and Helix-Constrained Peptides with High Affinity and Specificity for the cFos Coiled-Coil of AP-1. Plos One. 2013; 8:e59415. doi: 10.1371/journal.pone.0059415 PMID: 23544065